SAB Biotherapeutics (NASDAQ:SABS) Earns Buy Rating from Analysts at Rodman & Renshaw

Rodman & Renshaw started coverage on shares of SAB Biotherapeutics (NASDAQ:SABS) in a research report sent to investors on Thursday morning, Marketbeat reports. The brokerage issued a buy rating and a $13.00 price target on the stock.

A number of other research firms have also recently issued reports on SABS. Wall Street Zen cut SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Zacks Research lowered SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a report on Thursday, March 12th. UBS Group assumed coverage on SAB Biotherapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $7.00 price target on the stock. Guggenheim assumed coverage on SAB Biotherapeutics in a report on Friday, December 19th. They set a “buy” rating and a $15.00 price target for the company. Finally, HC Wainwright reduced their price objective on shares of SAB Biotherapeutics from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Tuesday, March 10th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.50.

SAB Biotherapeutics Price Performance

SABS opened at $3.88 on Thursday. The stock has a market capitalization of $197.69 million, a P/E ratio of -1.67 and a beta of 0.60. The company’s 50 day simple moving average is $4.01 and its 200-day simple moving average is $3.55. SAB Biotherapeutics has a one year low of $1.00 and a one year high of $6.60. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.46 and a quick ratio of 9.46.

SAB Biotherapeutics (NASDAQ:SABS) last issued its earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.30). Sell-side analysts anticipate that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Hedge Funds Weigh In On SAB Biotherapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC bought a new position in shares of SAB Biotherapeutics during the fourth quarter worth approximately $3,004,000. Millennium Management LLC bought a new stake in SAB Biotherapeutics in the 4th quarter valued at $1,212,000. Balyasny Asset Management L.P. bought a new stake in SAB Biotherapeutics in the 4th quarter valued at $1,778,000. ADAR1 Capital Management LLC grew its holdings in SAB Biotherapeutics by 75.6% in the 4th quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock valued at $99,000 after buying an additional 11,344 shares in the last quarter. Finally, ExodusPoint Capital Management LP bought a new position in SAB Biotherapeutics during the 4th quarter worth $322,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.